Ultragenyx Pharmaceutical Inc.
RAREHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeUltragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare. With a market capitalization of $2.30B, it sits in mid-cap territory. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Market Cap
$2.30B
Beta
0.39
P/E (TTM)
—
P/E (Fwd)
24.23
EPS (TTM)
$-6.16
EPS (Fwd)
$0.97
ROE
—
ROA
-25.4%
Cash
$413.0M
Total Debt
$1.20B
Free CF
-$219.1M
52W Change
-33.2%
Annual Financials
Cash vs Debt
On the balance sheet, RARE has $413.0M in cash with $1.20B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$219.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has grown from $363.3M (2022) to $673.0M (2025), reflecting a 85% increase over the period.
With a beta below 0.7, Ultragenyx Pharmaceutical Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing RARE.